The STAR Prospective Clinical Series

The DFINE STAR™ Tumor Ablation Prospective Clinical Series

Prospective clinical series to gather post tumor ablation clinical outcomes from subjects with painful spinal metastases following targeted radiofrequency ablation (t-RFA) treatment with the STAR™ Tumor Ablation System.

Inclusion Criteria:

• The STAR™ Tumor Ablation System is indicated for palliative treatment in spinal procedures by ablation of metastatic malignant lesions in a vertebral body.

Exclusion Criteria:

• The device is contraindicated in subjects with heart pacemakers, or other electronic device implants.
• The device is contraindicated in vertebral body levels C1-7.